

In the Claims:

Please cancel claims 4-7, 9-17, 25– 30.

5

Amended claims:

1. A method of treating a condition amenable to treatment by promoting angiogenesis, said method comprising administering a composition to a subject in need thereof an amount of a Nicotine,
10 nicotinic acid analogs, or polymeric forms thereof, effective for promoting angiogenesis in said subject.
2. (Old Claim 3). The method of claim 1, wherein the Nicotine, nicotinic acid analogs is conjugated to a member selected from the group consisting of: polyvinyl alcohol, acrylic acid ethylene co-
15 polymer, polyethylene glycol (PEG), and polylactic acid.
3. (Old Claim 21 and 22). The method of claim 1, wherein said polymer is polyvinyl alcohol, acrylic acid ethylene co-polymer, polyethylene glycol (PEG), polylactic acid, or agarose.
- 20 4. (Old Claim 23). The angiogenic agent of claim 3, wherein said conjugation is via a covalent or non-covalent bond.
5. (Old Claim 23). The angiogenic agent of claim 6, wherein said covalent bond is an ester linkage, ether linkage, or an anhydride linkage.

6. (New). The method of Claim 1, wherein the Nicotine and Nicotinic acid derivatives are combined in different proportions ranging from 0.001 mg – 10 mg.

7. (Old Claim 10). The method of Claim 1, wherein the Nicotine and Nicotinic acid analogs or
5 their polymeric forms are encapsulated in nanoparticles of < 1000 nanometer, microparticles > 1000 nanometer, liposome or polymers.

8. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by promoting angiogenesis is selected from the group consisting of: occlusive vascular disease.

10 9. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by promoting angiogenesis is selected from the group consisting of: coronary disease.

10. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by promoting angiogenesis is selected from the group consisting of: myocardial infarction.

15

11. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by promoting angiogenesis is selected from the group consisting of: ischemia, stroke.

12. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by
20 promoting angiogenesis is selected from the group consisting of: peripheral artery vascular disorders.

13. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by promoting angiogenesis is selected from the group consisting of: erectile dysfunction.

5 14. (Old Claim 2). The method of claim 1, wherein said condition amenable to treatment by promoting angiogenesis is selected from the group consisting of: impaired wound healing, foot ulcer.

15 15. (Old claim 8). The method of claim 1, wherein the mode of administration of Nicotine, nicotinic acid analogs or polymeric forms thereof, is parenteral, oral, rectal, topical, or combinations thereof.

16. (Old Claim 18). A method for promoting angiogenesis applied with a medical device, said method comprising coating the device with a nicotine, nicotinic acid analogs, or polymeric forms thereof, prior to inserting the device into a patient.

17. (Old Claim 19). Method of claim 5, wherein said coating step further comprises coating the device with a growth factor, a vasodilator, an anti-coagulant, or combinations thereof.

20 18. (Old Claim 20). The method of claim 5, wherein said medical device is a stent, a catheter, a cannula, or an electrode.